JP6784668B2 - 相乗的オーリスタチン組合せ - Google Patents

相乗的オーリスタチン組合せ Download PDF

Info

Publication number
JP6784668B2
JP6784668B2 JP2017518541A JP2017518541A JP6784668B2 JP 6784668 B2 JP6784668 B2 JP 6784668B2 JP 2017518541 A JP2017518541 A JP 2017518541A JP 2017518541 A JP2017518541 A JP 2017518541A JP 6784668 B2 JP6784668 B2 JP 6784668B2
Authority
JP
Japan
Prior art keywords
auristatin
pharmaceutically acceptable
cancer
pi3k
adc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017518541A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017530983A5 (OSRAM
JP2017530983A (ja
Inventor
サプラ プヤ
サプラ プヤ
ショア ボリス
ショア ボリス
Original Assignee
ファイザー・インク
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ファイザー・インク filed Critical ファイザー・インク
Publication of JP2017530983A publication Critical patent/JP2017530983A/ja
Publication of JP2017530983A5 publication Critical patent/JP2017530983A5/ja
Application granted granted Critical
Publication of JP6784668B2 publication Critical patent/JP6784668B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/402—1-aryl substituted, e.g. piretanide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6857—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from lung cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2017518541A 2014-10-10 2015-09-29 相乗的オーリスタチン組合せ Active JP6784668B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462062192P 2014-10-10 2014-10-10
US62/062,192 2014-10-10
PCT/IB2015/057457 WO2016055907A1 (en) 2014-10-10 2015-09-29 Synergistic auristatin combinations

Publications (3)

Publication Number Publication Date
JP2017530983A JP2017530983A (ja) 2017-10-19
JP2017530983A5 JP2017530983A5 (OSRAM) 2018-11-08
JP6784668B2 true JP6784668B2 (ja) 2020-11-11

Family

ID=54288858

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017518541A Active JP6784668B2 (ja) 2014-10-10 2015-09-29 相乗的オーリスタチン組合せ

Country Status (12)

Country Link
US (1) US10617670B2 (OSRAM)
EP (2) EP3204005A1 (OSRAM)
JP (1) JP6784668B2 (OSRAM)
KR (1) KR20170058432A (OSRAM)
CN (1) CN107106685A (OSRAM)
AU (1) AU2015329625B2 (OSRAM)
BR (1) BR112017006113A8 (OSRAM)
CA (1) CA2907878A1 (OSRAM)
IL (1) IL251619B (OSRAM)
MX (1) MX2017004580A (OSRAM)
RU (1) RU2717570C2 (OSRAM)
WO (1) WO2016055907A1 (OSRAM)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3019559A4 (en) 2013-08-22 2017-04-05 Sony Corporation Water soluble fluorescent or colored dyes and methods for their use
KR102530707B1 (ko) 2016-04-01 2023-05-11 소니그룹주식회사 초휘도 이량체성 또는 중합체성 염료
KR20180133890A (ko) 2016-04-06 2018-12-17 소니 주식회사 스페이싱 링커 그룹을 포함하는 초고명도 이량체성 또는 중합체성 염료
EP3455300A1 (en) 2016-05-11 2019-03-20 Sony Corporation Ultra bright dimeric or polymeric dyes
US12018159B2 (en) 2016-07-29 2024-06-25 Sony Group Corporation Ultra bright dimeric or polymeric dyes and methods for preparation of the same
EP3691689A1 (en) 2017-10-05 2020-08-12 Sony Corporation Programmable dendritic drugs
JP7551056B2 (ja) 2017-10-05 2024-09-17 ソニーグループ株式会社 プログラマブルなポリマー薬物
WO2019088176A1 (ja) * 2017-10-31 2019-05-09 国立大学法人神戸大学 抗体薬物複合体効果増強剤
CN111836645A (zh) 2017-11-16 2020-10-27 索尼公司 可编程的聚合药物
AU2018375787B2 (en) * 2017-11-30 2023-02-23 Ladrx Corporation Albumin-binding prodrugs of auristatin E derivatives
WO2019140301A1 (en) 2018-01-12 2019-07-18 Sony Corporation Polymers with rigid spacing groups comprising biologically active compounds
EP4616912A3 (en) 2018-01-12 2025-11-19 Sony Group Corporation Phosphoalkyl ribose polymers comprising biologically active compounds
KR102742386B1 (ko) 2018-03-19 2024-12-16 소니그룹주식회사 형광 신호 향상을 위한 2가 금속의 사용
WO2019182766A1 (en) 2018-03-21 2019-09-26 Sony Corporation Polymeric tandem dyes with linker groups
KR102854332B1 (ko) 2018-06-27 2025-09-03 소니그룹주식회사 디옥시리보오스를 포함하는 링커 군을 갖는 중합체성 염료
KR102486779B1 (ko) 2019-09-26 2023-01-12 소니그룹주식회사 링커 그룹을 갖는 중합체성 탠덤 염료
JP7556194B2 (ja) * 2019-12-13 2024-09-26 Ｔｏｐｐａｎホールディングス株式会社 細胞構造体及びその使用
EP4256078A1 (en) 2020-12-07 2023-10-11 Sony Group Corporation Spacing linker group design for brightness enhancement in dimeric or polymeric dyes

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4846978B2 (ja) 2001-10-30 2011-12-28 メルク セローノ ソシエテ アノニム タンパク質チロシンホスファターゼのオキシンドールヒドラジンモジュレータ
PA8577501A1 (es) 2002-07-25 2004-02-07 Warner Lambert Co Inhibidores de quinasas
NZ583292A (en) * 2003-11-06 2012-03-30 Seattle Genetics Inc Monomethylvaline compounds capable of conjugation to ligands
CA2621502A1 (en) * 2005-09-07 2007-03-15 Medimmune, Inc. Toxin conjugated eph receptor antibodies
CN101542478B (zh) 2006-06-26 2012-07-18 尼尔森（美国）有限公司 提高数据仓库性能的方法和装置
HRP20110621T2 (hr) 2006-09-15 2013-12-06 Pfizer Products Inc. SPOJEVI PIRIDO[2,3-d]PIRIMIDINONA I NJIHOVA UPOTREBA KAO INHIBITORI PI3
CL2008001334A1 (es) * 2007-05-08 2008-09-22 Genentech Inc Anticuerpo anti-muc16 disenado con cisteina; conjugado que lo comprende; metodo de produccion; formulacion farmaceutica que lo comprende; y su uso para tratar el cancer.
KR101601986B1 (ko) 2007-10-02 2016-03-17 추가이 세이야쿠 가부시키가이샤 인터류킨 6 수용체 저해제를 유효 성분으로 하는 이식편대숙주병 치료제
EP2300483A1 (en) * 2008-05-23 2011-03-30 Wyeth LLC Triazine compounds as p13 kinase and mtor inhibitors
JP2013534520A (ja) * 2010-06-08 2013-09-05 ジェネンテック， インコーポレイテッド システイン操作抗体及びコンジュゲート
ES3004351T3 (en) 2010-10-22 2025-03-12 Seagen Inc Synergistic effects between auristatin-based antibody drug conjugates and inhibitors of the pi3k-akt mtor pathway
ES2596194T3 (es) 2011-04-01 2017-01-05 Wyeth Llc Conjugados de anticuerpo-fármaco
CA2850034A1 (en) * 2011-10-28 2013-05-02 Genentech, Inc. Therapeutic combinations and methods of treating melanoma
PT3327027T (pt) * 2011-11-17 2021-02-15 Pfizer Péptidos citotóxicos e seus conjugados de anticorpos e fármacos
BR112015010436A2 (pt) * 2012-11-07 2017-08-22 Pfizer Anticorpos anti-notch3 e conjugados anticorpo-fármaco
PT3137114T (pt) * 2014-04-30 2021-02-26 Pfizer Conjugados anticorpo-fármaco anti-ptk7

Also Published As

Publication number Publication date
BR112017006113A8 (pt) 2018-04-24
CA2907878A1 (en) 2016-04-10
EP3549583A1 (en) 2019-10-09
US20180228769A1 (en) 2018-08-16
US10617670B2 (en) 2020-04-14
CN107106685A (zh) 2017-08-29
RU2017112048A (ru) 2018-11-15
RU2017112048A3 (OSRAM) 2019-05-07
WO2016055907A1 (en) 2016-04-14
BR112017006113A2 (pt) 2017-12-19
EP3204005A1 (en) 2017-08-16
RU2717570C2 (ru) 2020-03-24
IL251619A0 (en) 2017-06-29
AU2015329625A1 (en) 2017-04-13
AU2015329625B2 (en) 2018-04-05
KR20170058432A (ko) 2017-05-26
IL251619B (en) 2020-10-29
JP2017530983A (ja) 2017-10-19
MX2017004580A (es) 2017-06-27

Similar Documents

Publication Publication Date Title
JP6784668B2 (ja) 相乗的オーリスタチン組合せ
JP2024161445A (ja) 抗体－薬物コンジュゲートとキナーゼ阻害剤の組み合わせ
CN108024540B (zh) 用于治疗癌症的方法
JP2025041725A (ja) 抗体－薬物コンジュゲートとｐａｒｐ阻害剤の組み合わせ
KR20120115237A (ko) 암 치료 방법 및 조성물
US20230330243A1 (en) Combination of antibody-drug conjugate and atr inhibitor
US20110165155A1 (en) Methods of treating metastatic breast cancer with trastuzumab-mcc-dm1
KR20140025434A (ko) Akt 억제제 화합물 및 화학요법제의 조합물, 및 사용 방법
JP2023502929A (ja) Ｈｅｒ２陽性乳がんを抗ｈｅｒ２抗体－薬物コンジュゲートと併用してツカチニブで治療する方法
JP2017503842A (ja) 癌治療のためのアピリモド（ａｐｉｌｉｍｏｄ）組成物
JP2023539715A (ja) 抗体－薬物コンジュゲートとａｔｍ阻害剤との組合わせ
JP2017536356A (ja) 肺の非小細胞癌及び多形性膠芽腫を処置するための放射線療法と一緒のジアンヒドロガラクチトール
MX2014010591A (es) Terapia combinada para el tratamiento de cancer de ovario.
AU2019201169A1 (en) Pim kinase inhibitor combinations
CN110996960A (zh) 第三代egfr酪氨酸激酶抑制剂和raf抑制剂的治疗组合
KR20210010524A (ko) 샘낭암종을 치료하기 위한 비스플루오로알킬-1,4-벤조디아제피논 화합물을 포함하는 조성물
KR20220008870A (ko) 노치-활성화 유방암을 치료하기 위한 비스플루오로알킬-1,4-벤조디아제피논 화합물
CN114302745A (zh) 包含抗cd19抗体药物缀合物以及pi3k抑制剂或第二剂的组合疗法
JP7673255B2 (ja) Ｍｃｌ－１阻害剤と抗体薬物コンジュゲートとの組み合わせ
HK1242995A1 (en) Synergistic auristatin combinations
WO2025049904A1 (en) Egfr inhibitor for use in the treatment of lung cancer positive for an egfr exon 20 mutation
EA049478B1 (ru) Комбинация конъюгата антитела и лекарственного средства и ингибитора atr
HK40054690A (en) Combination of antibody-drug conjugate and kinase inhibitor
Molife et al. 1202 ORAL A Phase I Study of the Potent AKT Inhibitor MK-2206 in Combination With Carboplatin and Paclitaxel, Docetaxel or Erlotinib in Patients With Advanced Solid Tumours

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180925

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180925

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190723

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20191011

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191028

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200106

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200311

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200521

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20201020

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20201023

R150 Certificate of patent or registration of utility model

Ref document number: 6784668

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250